182 related articles for article (PubMed ID: 35291211)
1. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication).
Hurst BL; Dickinson D; Hsu S
Microbiol Infect Dis; 2021; 5(2):. PubMed ID: 35291211
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
Dinda B; Dinda S; Dinda M
Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
[TBL] [Abstract][Full Text] [Related]
3. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
Henss L; Auste A; Schürmann C; Schmidt C; von Rhein C; Mühlebach MD; Schnierle BS
J Gen Virol; 2021 Apr; 102(4):. PubMed ID: 33830908
[TBL] [Abstract][Full Text] [Related]
4. An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection.
Bimonte S; Forte CA; Cuomo M; Esposito G; Cascella M; Cuomo A
Drug Des Devel Ther; 2021; 15():4447-4454. PubMed ID: 34737551
[TBL] [Abstract][Full Text] [Related]
5. Dual action of epigallocatechin-3-gallate in virus-induced cell Injury.
Mostafa A; Mostafa-Hedeab G; Elhady HA; Mohamed EA; Eledrdery AY; Alruwaili SH; Al-Abd AM; Allayeh AK
J Genet Eng Biotechnol; 2023 Nov; 21(1):145. PubMed ID: 38012348
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.
Liu J; Bodnar BH; Meng F; Khan AI; Wang X; Saribas S; Wang T; Lohani SC; Wang P; Wei Z; Luo J; Zhou L; Wu J; Luo G; Li Q; Hu W; Ho W
Cell Biosci; 2021 Aug; 11(1):168. PubMed ID: 34461999
[TBL] [Abstract][Full Text] [Related]
7. Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract.
Zhang Z; Hao M; Zhang X; He Y; Chen X; Taylor EW; Zhang J
Trends Food Sci Technol; 2023 Feb; 132():40-53. PubMed ID: 36594074
[TBL] [Abstract][Full Text] [Related]
8. Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID.
Frank N; Dickinson D; Garcia W; Liu Y; Yu H; Cai J; Patel S; Yao B; Jiang X; Hsu S
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399972
[TBL] [Abstract][Full Text] [Related]
9. The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.
Shin JA; Oh S; Jeong JM
Phytomed Plus; 2021 Nov; 1(4):100058. PubMed ID: 35403084
[TBL] [Abstract][Full Text] [Related]
10. The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor.
LeBlanc EV; Colpitts CC
Sci Rep; 2022 Jul; 12(1):12899. PubMed ID: 35902713
[TBL] [Abstract][Full Text] [Related]
11. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Antioxidant, Immunomodulatory Activity of Oxidised Epigallocatechin-3-Gallate (Green Tea Polyphenol) and Its Action on the Main Protease of SARS-CoV-2-An In Vitro and In Silico Approach.
Ungarala R; Munikumar M; Sinha SN; Kumar D; Sunder RS; Challa S
Antioxidants (Basel); 2022 Jan; 11(2):. PubMed ID: 35204178
[TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
Ngwe Tun MM; Luvai E; Nwe KM; Toume K; Mizukami S; Hirayama K; Komatsu K; Morita K
Arch Virol; 2022 Jul; 167(7):1547-1557. PubMed ID: 35606466
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.
Hong S; Seo SH; Woo SJ; Kwon Y; Song M; Ha NC
J Agric Food Chem; 2021 Jun; 69(21):5948-5954. PubMed ID: 34015930
[TBL] [Abstract][Full Text] [Related]
15. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
[TBL] [Abstract][Full Text] [Related]
16. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.
Zhang Z; Zhang X; Bi K; He Y; Yan W; Yang CS; Zhang J
Trends Food Sci Technol; 2021 Aug; 114():11-24. PubMed ID: 34054222
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
Cell Rep; 2020 Jul; 32(3):107940. PubMed ID: 32668216
[TBL] [Abstract][Full Text] [Related]
18. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Novel Nasal Mucoadhesive Nanoformulations Containing Lipid-Soluble EGCG for Long COVID Treatment.
Frank N; Dickinson D; Lovett G; Liu Y; Yu H; Cai J; Yao B; Jiang X; Hsu S
Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931912
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
bioRxiv; 2020 Apr; ():. PubMed ID: 32511392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
